| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Allogene Therapeutics (NASDAQ:ALLO) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:02 PM.
Here's what investors need to know about the announcement.
Allogene Therapeutics missed estimated earnings by -13.0%, reporting an EPS of $-0.51 versus an estimate of $-0.45.
Revenue was down $26 thousand from the same period last year.
Last quarter the company beat on EPS by $0.15 which was followed by a 18.0% increase in the share price the next day.
Here's a look at Allogene Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.52 | -0.59 | -0.62 | -0.70 |
| EPS Actual | -0.37 | -0.53 | -0.68 | -0.66 |
| Revenue Estimate | 10K | 70K | 10K | 60K |
| Revenue Actual | 43K | 44K | 52K | 47K |
To track all earnings releases for Allogene Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ALLO
